Frontida BioPharm acquires Philadelphia & Aurora facilities from Sun Pharmaceuticals
Philadelphia, PA – June 4, 2016: Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, today announced that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma.
AdaptDose™, The innovation in drug development, that reduces development time by up to 30%
Frontida’s AdaptDose™ technology platform provides a tool that can eliminate the need to reformulate after Phase I and overcomes several technical hurdles in the development and scale up of (1) new molecules, (2) binary and tertiary mixtures of active ingredients, zero and first order drug release matrices, or (3) scalable clinical trial materials used in dose ranging or adaptive dose clinical studies.
For Veteran’s Day 2016, Frontida employees teamed up with the Philadelphia Veterans Multi-Service Center, the Connect Church Philadelphia, and Grayson Sky to donate over 1,100 pounds of food for the US service men and women who served our country faithfully in the armed services. The food enabled many to have a better Thanksgiving this year!
Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization located in Philadelphia, PA and Aurora, IL announces that the Food and Drug Administration ("FDA") has issued a closure letter for its Philadelphia manufacturing site on May 4, 2017.
Frontida BioPharm and TruPharma Finalize Partnership For Marketing of 5 Products
Frontida BioPharm, Inc. a Contract Development and Manufacturing Organization with headquarters in Philadelphia, PA announced that it has entered into an exclusive agreement with TruPharma, LLC to market and distribute five ANDAs.